 Patients receive pomalidomide orally PO daily on days 1-21, dexamethasone PO twice weekly BIW or thrice weekly TIW weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW on weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. 